This website uses tracking technologies, such as cookies, to provide a better user experience. If you continue to use this site, then you acknowledge our use of tracking technologies. For additional information, review our Privacy Policy.
Adoptive cell transfer (ACT)—including CAR T cells—has achieved remarkable success against some cancers, especially blood cancers. However, sometimes these T cells become inactivated prematurely. Dr. Villadangos found that this can happen is if the density of tumor cells is too high. He termed this phenomenon “stunning” and now he is determining what causes it. He’s also characterizing the broader relationship between tumor and immune cells and determining how they influence anti-cancer immune responses. Overall, Dr. Villadangos’ work will hopefully suggest ways to address stunning and augment current ACT approaches.
The University of Melbourne (Australia) | All Cancers | 2016
Contact Us
Cancer Research Institute | National Headquarters 29 Broadway, Floor 4 | New York, NY 10006-3111
800-992-2623212-832-9376Staff Directory
Dr. Benjamin Vincent recaps highlights from Day 4 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference, covering cancer vaccines and innovative technologies to study tumor immunity.
Dr. E. John Wherry dicusses cell therapies and the cancer ecosystem during Day 3 of the 2022 CRI-ENCI-AACR International Cancer Immunotherapy Conference (CICON22).